{"id":4952,"date":"2015-11-12T08:02:14","date_gmt":"2015-11-12T08:02:14","guid":{"rendered":"https:\/\/jurmed.ro\/medici\/?p=4952"},"modified":"2015-11-12T08:05:02","modified_gmt":"2015-11-12T08:05:02","slug":"comunicat-de-presa-bristol-myers-squibb","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/","title":{"rendered":"Comunicat de pres\u0103 Bristol-Myers Squibb"},"content":{"rendered":"<p><em>\u00a0<img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4953\" src=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg\" alt=\"medalie\" width=\"300\" height=\"191\" srcset=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg 300w, https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie.jpg 402w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Opdivo (nivolumab), medicamentul dezvoltat de c\u0103tre Bristol-Myers Squibb prime\u015fte Premiul Galien USA 2015 pentru \u201cCel mai bun Produs Biotehnologic\u201d<\/strong><\/p>\n<p><em>Distinc\u0163ia recunoa\u015fte inova\u0163ia aplicat\u0103 de c\u0103tre echipa Bristol-Myers Squibb \u00een descoperirea \u015fi dezvoltarea inhibitorului PD-1 <\/em>Opdivo<em> (nivolumab), pentru tratamentul melanomului avansat \u015fi a cancerului pulmonar scuamos altul dec<\/em><em>\u00e2t cel cu celule mici.<\/em><\/p>\n<p><em>Este al doilea premiu Prix Galien USA acordat portofoliului imuno-oncologic al Bristol-Myers Squibb. \u00cen 2012, aceeasi dinstinc\u0163ie era acordat\u0103 medicamentului <\/em>Yervoy<em> (ipilimumab).<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>10 Noiembrie 2015 &#8211; Bristol-Myers Squibb anun\u0163\u0103 primirea distinc\u0163iei Prix Galien USA 2015, \u201cCel mai bun Produs Biotehnologic\u201d, pentru medicamentul Opdivo (<em>nivolumab<\/em>), inhibitorul PD-1 dezvoltat de c\u0103tre companie. Decernarea a avut loc \u00een timpul celei de-a noua edi\u0163ii anuale a Prix Galien USA din 27 octombrie 2015, la New York. Acest premiu este acordat de c\u0103tre o comisie \u015ftiin\u0163ific\u0103 de elit\u0103 ce include laurea\u0163i ai premiului Nobel \u015fi recunoa\u015fte rezultate remarcabile ob\u0163inute pentru dezvoltarea unor terapii inovative pentru \u00eembun\u0103t\u0103\u0163irea vie\u0163ii oamenilor.<\/p>\n<p>Distinc\u0163ia Prix Galien USA de anul acesta este cel de-al doilea titlu decernat companiei pentru categoria \u201cCel mai bun Produs Biotehnologic\u201d, Bristol-Myers Squibb fiind astfel singura companie care prime\u015fte acest premiu pentru dou\u0103 produse imuno-oncologice. \u00cen 2012, premiul a fost acordat medicamentului Yervoy \u00een urma aprob\u0103rii ini\u0163iale a acestuia pentru melanom nerezecabil sau avansat. Fiind un deschiz\u0103tor de drum \u00een imuno-oncologie, Bristol-Myers Squibb continu\u0103 s\u0103 cerceteze poten\u0163ialul acestei \u015ftiin\u0163e de avangard\u0103 pentru a cre\u015fte rata de supravie\u0163uire \u00een cazul unora dintre cele mai dificil de tratat tipuri de cancer.<\/p>\n<p>\u201cSuntem onora\u0163i de faptul c\u0103 prin acest premiu este recunoscut\u0103 contribu\u0163ia \u015ftiin\u0163ific\u0103 a companiei noastre la acest moment istoric \u00een cercetarea oncologic\u0103, acum c\u00e2nd imuno-oncologia schimb\u0103 a\u015ftept\u0103rile \u00een tratarea cancerului\u201d, spune Francis Cuss, MB BChir, FRCP, Vicepre\u015fedinte Executiv \u015fi Director \u015etiin\u0163ific, Bristol-Myers Squibb. \u201cAcordarea distinc\u0163iei Prix Galien USA 2015 subliniaz\u0103 eforturile noastre de cercetare clinic\u0103 pentru Opdivo \u00een ceea ce prive\u015fte unele dintre cele mai dificil de tratat tipuri de cancer precum melanomul avansat \u015fi cancerul pulmonar altul dec\u00e2t cel cu celule mici.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Despre Opdivo<\/strong><\/p>\n<p>Bristol-Myers Squibb de\u0163ine un program global amplu de dezvoltare pentru a studia Opdivo \u00een diverse tipuri de tumori, const\u00e2nd \u00een peste 50 de studii clinice \u2013 \u00een monoterapie sau \u00een combina\u0163ie cu alte terapii \u2013 \u00een care au fost \u00eenrola\u0163i peste 8.000 de pacien\u0163i la nivel mondial.<\/p>\n<p>Opdivo a fost primul inhibitor PD-1 la nivel mondial care a primit aprobarea autorit\u0103\u0163ilor de reglementare \u00een iulie 2014, iar \u00een prezent de\u0163ine autorizatie de punere pe pia\u0163\u0103 \u00een peste 37 de \u0163\u0103ri incluz\u00e2nd Statele Unite, Japonia \u015fi Uniunea European\u0103.<\/p>\n<p>Informa\u0163iile detaliate, aprobate la acest moment, privind indica\u0163iile de prescriere pentru Yervoy (ipilimumab) sunt disponibile pe site-ul Agen\u0163iei Europene a Medicamentului (EMA), accesand link-ul <a href=\"http:\/\/www.ema.europa.eu\/docs\/ro_RO\/document_library\/EPAR_-_Product_Information\/human\/002213\/WC500109299.pdf\">http:\/\/www.ema.europa.eu\/docs\/ro_RO\/document_library\/EPAR_-_Product_Information\/human\/002213\/WC500109299.pdf<\/a>, iar pentru Opdivo (nivolumab), pe site-ul Comisiei Europene,\u00a0 <a href=\"http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20151028133285\/anx_133285_ro.pdf\">http:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20151028133285\/anx_133285_ro.pdf<\/a><\/p>\n<p><strong><u>\u00a0<\/u><\/strong><\/p>\n<p><strong><u>Despre Bristol-Myers Squibb<\/u><\/strong><\/p>\n<p>Bristol-Myers Squibb este o companie farmaceutic\u0103 global\u0103 a c\u0103rei misiune este s\u0103 descopere, s\u0103 dezvolte \u015fi s\u0103 ofere medicamente inovatoare care \u00eei ajut\u0103 pe pacien\u0163i s\u0103 \u00eenving\u0103 bolile grave. Pentru mai multe informa\u0163ii despre Bristol-Myers Squibb, vizita\u0163i <a href=\"http:\/\/www.b-ms.ro\">www.b-ms.ro<\/a><\/p>\n<p><strong>Declara\u0163ia prospectiv\u0103 a companiei Bristol-Myers Squibb<br \/>\n<\/strong><em>Acest comunicat de pres\u0103 con\u0163ine \u201edeclara\u0163ii prospective&#8221;, un termen definit \u00een Legea privind reforma litigiilor privind valorile mobiliare private din 1995 cu privire la cercetarea, dezvoltarea \u015fi comercializarea produselor farmaceutice. Aceste declara\u0163ii prospective au la baz\u0103 a\u015ftept\u0103rile actuale \u015fi implic\u0103 riscuri \u015fi incertitudini inerente, inclusiv factori care ar putea \u00eent\u00e2rzia, devia sau modifica oricare dintre acestea, \u015fi pot determina diferen\u0163e semnificative ale rezultatelor \u015fi consecin\u0163elor efective fa\u0163\u0103 de a\u015ftept\u0103rile actuale. Declara\u0163iile prospective nu pot fi garantate. Declara\u0163iile prospective din acest comunicat de pres\u0103 trebuie evaluate \u00eempreun\u0103 cu numeroasele incertitudini din activitatea comercial\u0103 a companiei Bristol-Myers Squibb, \u00een special cele identificate \u00een discu\u0163ia privind factorii de preven\u0163ie din Raportul anual al companiei Bristol-Myers Squibb asupra Formularului 10-K pentru anul \u00eencheiat la 31 decembrie 2014, \u00een Rapoartele noastre trimestriale asupra Formularului 10-Q \u015fi Rapoartele noastre actuale asupra Formularului 8-K. <\/em><\/p>\n<p><em>Bristol-Myers Squibb nu \u00ee\u015fi asum\u0103 nicio obliga\u0163ie \u00een sensul revizuirii publice a oric\u0103reia dintre declara\u0163iile prospective, fie \u00een urma apari\u0163iei de noi informa\u0163ii,\u00a0 evenimente viitoare\u00a0 sau al\u021bi factori.<\/em><\/p>\n<p><em>\u00a0<\/em><\/p>\n<p><strong>Contact pentru pres\u0103<\/strong><strong>:<\/strong><\/p>\n<p>Sorana Kunst, Public Affairs Manager<\/p>\n<p><a href=\"mailto:sorana.kunst@bms.com\">sorana.kunst@bms.com<\/a> \/ +40 21 272 16 51 \/ +40 732 015 091<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 &nbsp; Opdivo (nivolumab), medicamentul dezvoltat de c\u0103tre Bristol-Myers Squibb prime\u015fte Premiul Galien USA 2015 pentru \u201cCel mai bun Produs Biotehnologic\u201d Distinc\u0163ia recunoa\u015fte inova\u0163ia aplicat\u0103 de c\u0103tre echipa Bristol-Myers Squibb [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4952","post","type-post","status-publish","format-standard","category-stiri-noutati"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comunicat de pres\u0103 Bristol-Myers Squibb - Jurmed - Medici<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comunicat de pres\u0103 Bristol-Myers Squibb - Jurmed - Medici\" \/>\n<meta property=\"og:description\" content=\"\u00a0 &nbsp; Opdivo (nivolumab), medicamentul dezvoltat de c\u0103tre Bristol-Myers Squibb prime\u015fte Premiul Galien USA 2015 pentru \u201cCel mai bun Produs Biotehnologic\u201d Distinc\u0163ia recunoa\u015fte inova\u0163ia aplicat\u0103 de c\u0103tre echipa Bristol-Myers Squibb [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Medici\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-12T08:02:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-11-12T08:05:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg\" \/>\n<meta name=\"author\" content=\"costelv\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"costelv\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\"},\"author\":{\"name\":\"costelv\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"headline\":\"Comunicat de pres\u0103 Bristol-Myers Squibb\",\"datePublished\":\"2015-11-12T08:02:14+00:00\",\"dateModified\":\"2015-11-12T08:05:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\"},\"wordCount\":765,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg\",\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\",\"url\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\",\"name\":\"Comunicat de pres\u0103 Bristol-Myers Squibb - Jurmed - Medici\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg\",\"datePublished\":\"2015-11-12T08:02:14+00:00\",\"dateModified\":\"2015-11-12T08:05:02+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie.jpg\",\"width\":402,\"height\":256},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/medici\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comunicat de pres\u0103 Bristol-Myers Squibb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\",\"url\":\"https:\/\/jurmed.ro\/medici\/\",\"name\":\"Jurmed - Medici\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/medici\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\",\"name\":\"costelv\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"caption\":\"costelv\"},\"url\":\"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comunicat de pres\u0103 Bristol-Myers Squibb - Jurmed - Medici","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/","og_locale":"ro_RO","og_type":"article","og_title":"Comunicat de pres\u0103 Bristol-Myers Squibb - Jurmed - Medici","og_description":"\u00a0 &nbsp; Opdivo (nivolumab), medicamentul dezvoltat de c\u0103tre Bristol-Myers Squibb prime\u015fte Premiul Galien USA 2015 pentru \u201cCel mai bun Produs Biotehnologic\u201d Distinc\u0163ia recunoa\u015fte inova\u0163ia aplicat\u0103 de c\u0103tre echipa Bristol-Myers Squibb [&hellip;]","og_url":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/","og_site_name":"Jurmed - Medici","article_published_time":"2015-11-12T08:02:14+00:00","article_modified_time":"2015-11-12T08:05:02+00:00","og_image":[{"url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg","type":"","width":"","height":""}],"author":"costelv","twitter_misc":{"Scris de":"costelv","Timp estimat pentru citire":"4 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/"},"author":{"name":"costelv","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"headline":"Comunicat de pres\u0103 Bristol-Myers Squibb","datePublished":"2015-11-12T08:02:14+00:00","dateModified":"2015-11-12T08:05:02+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/"},"wordCount":765,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg","articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/","url":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/","name":"Comunicat de pres\u0103 Bristol-Myers Squibb - Jurmed - Medici","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie-300x191.jpg","datePublished":"2015-11-12T08:02:14+00:00","dateModified":"2015-11-12T08:05:02+00:00","author":{"@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"breadcrumb":{"@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#primaryimage","url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie.jpg","contentUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/11\/medalie.jpg","width":402,"height":256},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/medici\/comunicat-de-presa-bristol-myers-squibb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/medici\/"},{"@type":"ListItem","position":2,"name":"Comunicat de pres\u0103 Bristol-Myers Squibb"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/medici\/#website","url":"https:\/\/jurmed.ro\/medici\/","name":"Jurmed - Medici","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/medici\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d","name":"costelv","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","caption":"costelv"},"url":"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/comments?post=4952"}],"version-history":[{"count":2,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4952\/revisions"}],"predecessor-version":[{"id":4955,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4952\/revisions\/4955"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media?parent=4952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/categories?post=4952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/tags?post=4952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}